Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 12, 2014, Pages 3455-3465

  Einstein, Mark H ^a   Levin, Myron J ^b   Chatterjee, Archana ^c   Chakhtoura, Nahida ^d   Takacs, Peter ^d   Catteau, Grégory ^e   Dessy, Francis J ^e   Moris, Philippe ^e   Lin, Lan ^f   Struyf, Frank ^e   Dubin, Gary ^g   Blatter, Mark ^h   Chambers, Christopher V ⁱ   Fernandez, Marina ^j   Fox, Bradley ^k   Fried, David L ^l   Funk, Sidney A ^m   Hansen, Cheryl A ⁿ   Hedrick, James A ^o   Hoffman, Bethany ^p   Klein, Terry D ^q   Lalezari, Jacob ^r   Noss, Michael J ^m   Silverblatt, James H ^s   Sperling, Rhoda S ^t   Swenson, Karen G ^u   Thompson, Troy ^v   Turner, Mark ^w   Warren, Michael W ^x   Yoachim, Robert ^q   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e GSK   (Belgium)

^f XPePharma and Science   (Belgium)

^g GLAXOSMITHKLINE   (United States)

^h Primary Physicians Research Inc   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j Center for Clinical Trials of San Gabriel   (United States)

^k Liberty Family Practice   (United States)

^l Omega Medical Research   (United States)

^m RADIANT RESEARCH   (United States)

ⁿ Ridgeview Research   (United States)

^o Kentucky Pediatric Research Institute   (United States)

^p Aspen Medical Group   (United States)

^q Heartland Research Associates   (United States)

^r Quest Clinical Research   (United States)

^s Lake Medical Research   (United States)

^t MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^u Professional Quality Research   (United States)

^v Southwestern Medical Clinic PC   (United States)

^w Advanced Clinical Research   (United States)

^x Research Across America   (United States)

more..

Author keywords

Cervarix ; Gardasil ; Human papillomavirus; Immunogenicity; Safety

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODILY SECRETIONS; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CERVICOVAGINAL SECRETION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; MEMORY CELL; MIDDLE AGED; NONHUMAN; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; VIRUS ASSEMBLY; VIRUS NEUTRALIZATION; YOUNG ADULT; ADOLESCENT; B LYMPHOCYTE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC MEMORY; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84922588675     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.36117     Document Type: Article

References (26)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AIDPATH431% 3e3.0.CO;2-F
2. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-26; PMID:12543621; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
3. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi L-F, Stern ME, Lee S-K, O'Reilly SF, Hawes SE, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196:1125-36; PMID:17955429; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
4. Castellsague X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009; 115:S15-23; PMID:19819540; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
5. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine 2007; 25 Suppl 3:C1-26; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AIDPATH431% 3e3.0.CO;2-F
6. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128:927-35; PMID:20473886; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
7. Garcon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011; 25:217-26; PMID:21815697; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
8. Paavonen J, Jenkins D, Bosch F, Naud P, Salmeron J, Wheeler C, Chow S, Apter D, Kitchener H, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH 431%3e3.0.CO;2-F
9. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AIDPATH431% 3e3.0.CO;2-F
10. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85; PMID:19962185; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
11. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66; PMID:17117182; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
12. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705-19; PMID:19684472; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
13. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7:1343-58; PMID:22048173; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
14. Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S. A randomized, observer-blinded immunogenicity trial of Cervarix® and Gardasil® Human Papillomavirus vaccines in 12-15 year old girls. PLoS One 2013; 8: e61825; PMID:23650505; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH 431%3e3.0.CO;2-F
15. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49; PMID:16828940; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12:: AID-PATH431%3e3.0.CO;2-F
16. Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff AS, Kroger N, et al. An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. J Immunol Methods 2010; 358:56-65; PMID:20302874; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AIDPATH431% 3e3.0.CO;2-F
17. Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine 2012; 31:234-41; PMID:23063422; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AIDPATH431% 3e3.0.CO;2-F
18. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9; PMID:17499406; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AIDPATH431% 3e3.0.CO;2-F
19. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, et al; HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27:581-7; PMID:19022320; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AIDPATH431% 3e3.0.CO;2-F
20. Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccin Immunother 2014; 10:1155-65; PMID:24576907; http://dx.doi.org/10.1002/(SICI)1096-9896(199909) 189:1%3c12::AID-PATH431%3e3.0.CO;2-F
21. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic nonvaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359-73; PMID:22048172; http://dx.doi.org/10.1002/(SICI) 1096-9896(199909)189:1%3c12::AID-PATH431% 3e3.0.CO;2-F
22. Centres for Disease Control and Prevention. Vaccine Safety: Human Papillomavirus (HPV) Vaccine [Internet]. Updated December 20, 2013; cited January 29, 2014. Available from: http://www.cdc.gov/vaccinesafety/vaccines/HPV/Index.html.
23. Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, David M-P, Lin L, Struyf F, et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-ofstudy analysis of a Phase III randomized trial. Hum Vaccin Immunother (in submission).
24. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65; PMID:15541448; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH 431%3e3.0.CO;2-F
25. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34; PMID:18948732; http://dx. doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c 12::AID-PATH431%3e3.0.CO;2-F
26. Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clinical Immunol 2011; 31:443-54; http://dx.doi.org/10.1002/(SICI)1096-9896(199909) 189:1%3c12::AID-PATH431%3e3.0.CO;2-F